Highbridge Capital Management’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Highbridge Capital Management’s Portfolio SCMP Stock Details SCMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-97,538	Closed	-$1.15M	–	2191
2017 Q3	$1.15M	Buy	97,538 +51,407	+111%	+$577K	0.02%	545
2017 Q2	$484K	Sell	46,131 -39,498	-46%	-$403K	0.01%	765
2017 Q1	$942K	Buy	+85,629	New	+$994K	0.01%	643
2016 Q1	–	Sell	-11,682	Closed	-$201K	–	2019
2015 Q4	$201K	Buy	+11,682	New	+$209K	﹤0.01%	1354
2015 Q2	–	Sell	-15,096	Closed	-$235K	–	1823
2015 Q1	$235K	Buy	+15,096	New	+$234K	﹤0.01%	1213

Other funds holding SCMP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Highbridge Capital Management's SCMP Position: Q4 2017 in Review

Highbridge Capital Management sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q4 2017, closing a stake of 97,538 shares — an estimated $1.15M sold.

Highbridge Capital Management first reported a position in SCMP in Q1 2015 and held it in 5 quarters. The position peaked at $1.15M in Q3 2017. 188 funds tracked by Wall St. Rank hold SCMP as of Q4 2017.

Highbridge Capital Management reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
Highbridge Capital Management sold 97,538 Sucampo Pharmaceuticals, Inc. shares in Q4 2017, an estimated $1.15M.
Highbridge Capital Management first reported a position in Sucampo Pharmaceuticals, Inc. in Q1 2015 and held it in 5 quarters.
Highbridge Capital Management's Sucampo Pharmaceuticals, Inc. position peaked at $1.15M in Q3 2017.
188 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q4 2017.

Based on Highbridge Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.